2022 Savings Offer for AJOVY is here. Learn more
AJOVY CGRP migraine prevention treatment injection

How is AJOVY different?

AJOVY has a long half-life of 31 days1

This information should not be construed to imply any difference in safety, efficacy, or other clinical outcome. View the safety profile of AJOVY.

Washout period defined as time until plasma concentrations of AJOVY are below a clinically relevant concentration and thus considered eliminated.

AJOVY is a fully humanized (IgG2Δa) monoclonal antibody that selectively targets the CGRP ligand1,3

MOA of AJOVY involves the selective binding of CGRP

CGRP ligand binding

The mechanism of action for AJOVY
involves exclusive binding of the CGRP

MOA of AJOVY shows no off-site binding

Off-site binding

AJOVY does not exhibit off-site binding
of related calcitonin family members

The long-acting anti-CGRP injection with monthly and quarterly dosing options1†‡

In clinical trials:

  • The most common adverse reactions in clinical trials (≥5% and greater than placebo) were injection-site reactions1
  • <1% of patients experienced constipation vs <1% with placebo4
  • <1% of patients experienced hypertension vs <1% with placebo4

Pharmacokinetic profile of AJOVY4,5

PHASE 1 STUDY ASSESSING PHARMACOKINETIC PARAMETERS

Month 1Month 3

The relationship between pharmacokinetics and efficacy has not been established.

AJOVY was evaluated in a phase 1 study to assess pharmacokinetic parameters for both monthly and quarterly dosing in healthy volunteers.5

Serum concentrations of AJOVY were sustained throughout both the monthly and quarterly dosing period4

Washout period defined as time until plasma concentrations of AJOVY are below a clinically relevant concentration and thus considered eliminated.

Watch the MOA video of AJOVY

Introducing AJOVY (fremanezumab-vfrm) injection, indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema.

AJOVY (fremanezumab-vfrm) injection is a monoclonal antibody targeting the calcitonin gene-related peptide, or CGRP, ligand.

Patients experiencing migraine have increased levels of CGRP, a neuropeptide present in both the central and peripheral nervous system.

When CGRP binds to its receptor, a cascade of events result, which contribute to neurogenic inflammation that is associated with migraine pain.

This involves mast cell degranulation, vasodilation, and protein extravasation.

AJOVY selectively binds the CGRP ligand, which is believed to block this cascade of events, thereby preventing the activation of the trigeminal system.

CGRP plays an important role in the pathophysiology of migraine.

INDICATION
AJOVY is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION
Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. Cases of anaphylaxis and angioedema have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

Adverse Reactions: The most common adverse reactions in clinical trials (≥5% and greater than placebo) were injection-site reactions.

Please see the full Prescribing Information at AJOVYhcp.com.

What to explore next